Avidity biosciences announces proposed public offering of common stock

San diego , aug. 13, 2024 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering. in addition, avidity intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of common stock.
RNA Ratings Summary
RNA Quant Ranking